tetano
Editor, Senior Moderator
J Gen Virol
. 2021 Apr;102(4).
doi: 10.1099/jgv.0.001578.
Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes
Katherine Davies[SUP] 1 [/SUP], Hubert Buczkowski[SUP] 1 [/SUP], Stephen R Welch[SUP] 1 [/SUP], Nicole Green[SUP] 1 [/SUP], Damian Mawer[SUP] 2 [/SUP], Neil Woodford[SUP] 3 [/SUP], Allen D G Roberts[SUP] 1 [/SUP], Peter J Nixon[SUP] 2 [/SUP], David W Seymour[SUP] 2 [/SUP], Marian J Killip[SUP] 1 [/SUP]
Affiliations
Abstract
Infectious SARS-CoV-2 can be recovered from the oral cavities and saliva of COVID-19 patients with potential implications for disease transmission. Reducing viral load in patient saliva using antiviral mouthwashes may therefore have a role as a control measure in limiting virus spread, particularly in dental settings. Here, the efficacy of SARS-CoV-2 inactivation by seven commercially available mouthwashes with a range of active ingredients were evaluated in vitro. We demonstrate ?4.1 to ?5.5 log[SUB]10[/SUB] reduction in SARS-CoV-2 titre following a 1 min treatment with commercially available mouthwashes containing 0.01-0.02 % stabilised hypochlorous acid or 0.58 % povidone iodine, and non-specialist mouthwashes with both alcohol-based and alcohol-free formulations designed for home use. In contrast, products containing 1.5 % hydrogen peroxide or 0.2 % chlorhexidine gluconate were ineffective against SARS-CoV-2 in these tests. This study contributes to the growing body of evidence surrounding virucidal efficacy of mouthwashes/oral rinses against SARS-CoV-2, and has important applications in reducing risk associated with aerosol generating procedures in dentistry and potentially for infection control more widely.
Keywords: COVID-19; SARS-CoV-2; coronavirus; inactivation; mouthwash; oral rinse.
. 2021 Apr;102(4).
doi: 10.1099/jgv.0.001578.
Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes
Katherine Davies[SUP] 1 [/SUP], Hubert Buczkowski[SUP] 1 [/SUP], Stephen R Welch[SUP] 1 [/SUP], Nicole Green[SUP] 1 [/SUP], Damian Mawer[SUP] 2 [/SUP], Neil Woodford[SUP] 3 [/SUP], Allen D G Roberts[SUP] 1 [/SUP], Peter J Nixon[SUP] 2 [/SUP], David W Seymour[SUP] 2 [/SUP], Marian J Killip[SUP] 1 [/SUP]
Affiliations
- PMID: 33913803
- DOI: 10.1099/jgv.0.001578
Abstract
Infectious SARS-CoV-2 can be recovered from the oral cavities and saliva of COVID-19 patients with potential implications for disease transmission. Reducing viral load in patient saliva using antiviral mouthwashes may therefore have a role as a control measure in limiting virus spread, particularly in dental settings. Here, the efficacy of SARS-CoV-2 inactivation by seven commercially available mouthwashes with a range of active ingredients were evaluated in vitro. We demonstrate ?4.1 to ?5.5 log[SUB]10[/SUB] reduction in SARS-CoV-2 titre following a 1 min treatment with commercially available mouthwashes containing 0.01-0.02 % stabilised hypochlorous acid or 0.58 % povidone iodine, and non-specialist mouthwashes with both alcohol-based and alcohol-free formulations designed for home use. In contrast, products containing 1.5 % hydrogen peroxide or 0.2 % chlorhexidine gluconate were ineffective against SARS-CoV-2 in these tests. This study contributes to the growing body of evidence surrounding virucidal efficacy of mouthwashes/oral rinses against SARS-CoV-2, and has important applications in reducing risk associated with aerosol generating procedures in dentistry and potentially for infection control more widely.
Keywords: COVID-19; SARS-CoV-2; coronavirus; inactivation; mouthwash; oral rinse.